Skip to main content
. Author manuscript; available in PMC: 2016 Mar 5.
Published in final edited form as: J Neurooncol. 2008 Sep 17;91(2):175–182. doi: 10.1007/s11060-008-9693-3

TABLE 5.

Summary of Results:

Study patients Control Group:
treated with RT
and non-TMZ
chemo
Control Group:
treated with RT
alone
Estimated 1-year survival 69.4% 57% 35%
Median survival 65 wks
(95% c.i. 54.8–74.2 wks)
57 wks
(95% c.i. 54–62 wks)
40 wks
(95% c.i. 36–44 wks)